Edition:
United States

Nymox Pharmaceutical Corp (NYMX.OQ)

NYMX.OQ on NASDAQ Stock Exchange Capital Market

3.53USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$3.53
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
29,906
52-wk High
$5.10
52-wk Low
$2.67

Chart for

About

Nymox Pharmaceutical Corp is a Canada-based biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company operates through the research and development of products for the... (more)
No analyst recommendations are available for .

Overall

Beta: 0.84
Market Cap(Mil.): $193.56
Shares Outstanding(Mil.): 54.83
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Nymox Pharmaceutical posts qtrly loss $0.09/shr - SEC filing‍​

* Nymox Pharmaceutical Corp qtrly loss per share $0.09 - SEC filing‍​ Source text: (http://bit.ly/2j7iBgX) Further company coverage:

Nov 06 2017

BRIEF-Nymox Pharmaceutical says ‍European member states accepted MAA​ for fexapotide triflutate

* Says ‍European member states for Nymox's MAA for fexapotide triflutate for treatment of benign prostatic hyperplasia accepted co's MAA​ Source text for Eikon: Further company coverage:

Sep 14 2017

BRIEF-Nymox Pharmaceutical postpones September 16 AUA meeting

* Says September 16 AUA meeting in Amelia Island, Florida postponed due to hurricane disaster in Florida​ Source text for Eikon: Further company coverage:

Sep 11 2017

BRIEF-Nymox announces private placements of $3 million

* Nymox announces private placements of $3 million Source text for Eikon: Further company coverage:

Aug 09 2017

BRIEF-Nymox Pharmaceutical Corp posts qtrly loss $0.05/shr - SEC filing‍​

* Nymox Pharmaceutical Corp says net losses were $2.7 million or $0.05 per share, for the quarter - SEC filing‍​

Aug 09 2017

Earnings vs. Estimates